Optas LLC’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.77M Buy
3,980
+43
+1% +$43.9K 0.67% 22
2026
Q1
$3.62M Buy
3,937
+49
+1% +$49.7K 0.55% 22
2025
Q4
$4.18M Sell
3,888
-3,392
-47% -$3.24M 0.65% 23
2025
Q3
$5.55M Buy
7,280
+3,789
+109% +$2.82M 0.94% 19
2025
Q2
$2.72M Buy
3,491
+48
+1% +$37.3K 0.52% 31
2025
Q1
$2.84M Sell
3,443
-453
-12% -$377K 0.49% 30
2024
Q4
$3.01M Sell
3,896
-373
-9% -$309K 0.65% 29
2024
Q3
$3.78M Buy
4,269
+1,668
+64% +$1.5M 0.87% 24
2024
Q2
$2.35M Buy
2,601
+100
+4% +$80K 0.61% 28
2024
Q1
$1.95M Buy
2,501
+53
+2% +$37.7K 0.53% 33
2023
Q4
$1.43M Buy
2,448
+374
+18% +$218K 0.43% 39
2023
Q3
$1.11M Buy
2,074
+825
+66% +$425K 0.37% 47
2023
Q2
$586K Buy
1,249
+66
+6% +$27.7K 0.2% 82
2023
Q1
$406K Buy
1,183
+89
+8% +$30K 0.15% 99
2022
Q4
$400K Buy
1,094
+52
+5% +$18.4K 0.17% 90
2022
Q3
$337K Buy
1,042
+22
+2% +$6.97K 0.15% 89
2022
Q2
$330K Buy
1,020
+188
+23% +$56.4K 0.14% 99
2022
Q1
$238K Buy
+832
New +$214K 0.08% 129
2020
Q4
Sell
-1,534
Closed -$226K 157
2020
Q3
$226K Buy
+1,534
New +$237K 0.07% 142

Other funds holding LLY

Optas LLC's LLY Position: Q2 2026 in Review

Optas LLC increased its Eli Lilly (LLY) stake by 1.1% in Q2 2026, buying an estimated $43.9K and bringing the position to 3,980 shares worth $4.77M. The position accounts for 0.67% of the portfolio, ranked #22.

Optas LLC first reported a position in LLY in Q3 2020 and has held it in 19 quarters since. The position peaked at $5.55M in Q3 2025. 1,393 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Optas LLC held 3,980 shares of Eli Lilly worth $4.77M as of Q2 2026.
  • Optas LLC bought 43 Eli Lilly shares in Q2 2026, an estimated $43.9K.
  • Eli Lilly made up 0.67% of Optas LLC's portfolio in Q2 2026, its #22 holding.
  • Optas LLC first reported a position in Eli Lilly in Q3 2020 and has held it in 19 quarters since.
  • Optas LLC's Eli Lilly position peaked at $5.55M in Q3 2025.
  • 1,393 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Optas LLC's 13F filing for Q2 2026, filed 21 Jul 2026.